Intra-Cellular Therapies Total Liabilities 2013-2022 | ITCI
Intra-Cellular Therapies total liabilities from 2013 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
- Intra-Cellular Therapies total liabilities for the quarter ending March 31, 2022 were $0.076B, a 21.64% increase year-over-year.
- Intra-Cellular Therapies total liabilities for 2021 were $0.072B, a 19.15% increase from 2020.
- Intra-Cellular Therapies total liabilities for 2020 were $0.06B, a 7.61% increase from 2019.
- Intra-Cellular Therapies total liabilities for 2019 were $0.056B, a 42.25% increase from 2018.
Intra-Cellular Therapies Annual Total Liabilities
(Millions of US $) |
| 2021 |
$72 |
| 2020 |
$60 |
| 2019 |
$56 |
| 2018 |
$39 |
| 2017 |
$17 |
| 2016 |
$13 |
| 2015 |
$8 |
| 2014 |
$11 |
| 2013 |
$7 |
| 2012 |
$3 |
Intra-Cellular Therapies Quarterly Total Liabilities
(Millions of US $) |
| 2022-03-31 |
$76 |
| 2021-12-31 |
$72 |
| 2021-09-30 |
$70 |
| 2021-06-30 |
$72 |
| 2021-03-31 |
$62 |
| 2020-12-31 |
$60 |
| 2020-09-30 |
$62 |
| 2020-06-30 |
$61 |
| 2020-03-31 |
$51 |
| 2019-12-31 |
$56 |
| 2019-09-30 |
$54 |
| 2019-06-30 |
$53 |
| 2019-03-31 |
$54 |
| 2018-12-31 |
$39 |
| 2018-09-30 |
$32 |
| 2018-06-30 |
$22 |
| 2018-03-31 |
$22 |
| 2017-12-31 |
$17 |
| 2017-09-30 |
$15 |
| 2017-06-30 |
$10 |
| 2017-03-31 |
$19 |
| 2016-12-31 |
$13 |
| 2016-09-30 |
$143 |
| 2016-06-30 |
$22 |
| 2016-03-31 |
$11 |
| 2015-12-31 |
$8 |
| 2015-09-30 |
$11 |
| 2015-06-30 |
$10 |
| 2015-03-31 |
$15 |
| 2014-12-31 |
$11 |
| 2014-09-30 |
$4 |
| 2014-06-30 |
$3 |
| 2014-03-31 |
$4 |
| 2013-12-31 |
$7 |
| 2013-09-30 |
$8 |
| 2013-06-30 |
$0 |
| 2013-03-31 |
$0 |
| 2012-12-31 |
|
| 2012-09-30 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$5.204B |
$0.084B |
|
Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.
|
